Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer's Disease
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- 3xTg-AD transgenic mice, a model of Alzheimer's disease
- Dose used in the study
- Ultramicronised PEA (um-PEA), 100 mg/kg/day, oral
- Duration
- 3 months
- What was measured
- Cognitive performance; IL-16 and TNF-alpha levels; reactive oxygen species production; synaptophysin and glutamate levels
What the authors reported
Chronic oral um-PEA was absorbed and reached the mice's brains. It rescued cognitive deficits, reduced neuroinflammation and oxidative stress, and lowered the raised hippocampal glutamate levels seen in 3xTg-AD mice.
Limits of this study
An animal model of Alzheimer's disease; it cannot show effect in people, though PEA is already licensed for use in humans for other indications. The authors declare no conflict of interest.
Source
PubMed 32033363 · doi:10.3390/jcm9020428
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.